HEALTHCARE
Global GLP-1 Analogues Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global GLP-1 Analogues Market, By Product (Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Mounjaro, Zepbound, Soliqua, Xultophy, Bydureon, and Others), Format (Single-Dose, Multi-Dose, and Tablets), Route of Administration (Subcutaneous and Oral), Indication (Diabetes, Obesity, and Others), End Use (Hospitals and Specialty Clinics, Long-Term Care Facilities, and Home Care Settings), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global GLP-1 Analogues market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
The global GLP-1 Analogues market involves drugs that mimic the effects of the glucagon-like peptide-1 (GLP-1) hormone, which plays a key role in glucose metabolism and appetite regulation. GLP-1 Analogues are synthetic versions of the naturally occurring GLP-1 hormone that help regulate blood glucose levels and promote weight loss by enhancing insulin secretion, reducing glucagon release, and slowing gastric emptying. These drugs are primarily used in the treatment of type 2 diabetes and, increasingly, obesity.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Rising incidence of type 2 diabetes
- Rising healthcare expenditure
RESTRAINTS
- High cost of treatment
- Competition from other diabetes medications
OPPORTUNITIES
- Focus on combination therapies
- Expansion into new indications
CHALLENGES
- Adverse effects and long-term safety
- Evolving and stringent regulatory landscape
SEGMENTATION
- Product
- Ozempic
- Wegovy
- Rybelsus
- Saxenda
- Victoza
- Trulicity
- Mounjaro
- Zepbound
- Soliqua
- Xultophy
- Bydureon
- Others
- Format
- Single-Dose
- Multi-Dose
- Tablets
- Route of Administration
- Subcutaneous
- Pen Injector
- Autoinjector
- Oral
- Indication
- Diabetes
- Obesity
- Others
- End Use
- Hospitals and Specialty Clinics
- Long-Term Care Facilities
- Home Care Settings
KEY MARKET PLAYERS
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd
- GSK
- Moderna
- Merck & Co., Inc.
- Hanmi Science
- Zealand Pharma
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global GLP-1 Analogues Market, by Product
- 3.2 Global GLP-1 Analogues Market, by Format
- 3.3 Global GLP-1 Analogues Market, by Route of Administration
- 3.4 Global GLP-1 Analogues Market, by Indication
- 3.5 Global GLP-1 Analogues Market, by End Use
- 3.6 Global GLP-1 Analogues Market, by Geography
- 3.7 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Patient-centric approaches
- 5.1.2 Regulatory approvals
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rising incidence of type 2 diabetes
- 5.2.2 Rising healthcare expenditure
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of treatment
- 5.3.2 Competition from other diabetes medications
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Focus on combination therapies
- 5.4.2 Expansion into new indications
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Adverse effects and long-term safety
- 5.5.2 Evolving and stringent regulatory landscape
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL GLP-1 ANALOGUES MARKET, BY PRODUCT
- 6.1 Product Summary
- 6.2 Market Attractive Index
- 6.3 Global GLP-1 Analogues Market, by Product (2019-2032)
- SECTION 7 - GLOBAL GLP-1 ANALOGUES MARKET, BY FORMAT
- 7.1 Format Summary
- 7.2 Market Attractive Index
- 7.3 Global GLP-1 Analogues Market, by Format (2019-2032)
- SECTION 8 - GLOBAL GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION
- 8.1 Route of Administration Summary
- 8.2 Market Attractive Index
- 8.3 Global GLP-1 Analogues Market, by Route of Administration (2019-2032)
- SECTION 9 - GLOBAL GLP-1 ANALOGUES MARKET, BY INDICATION
- 9.1 Indication Summary
- 9.2 Market Attractive Index
- 9.3 Global GLP-1 Analogues Market, by Indication (2019-2032)
- SECTION 10 - GLOBAL GLP-1 ANALOGUES MARKET, BY END USE
- 10.1 End Use Summary
- 10.2 Market Attractive Index
- 10.3 Global GLP-1 Analogues Market, by End Use (2019-2032)
- SECTION 11 - GLOBAL GLP-1 ANALOGUES MARKET, BY GEOGRAPHY
- 11.1 Regional Summary
- 11.2 Market Attractive Index
- 11.3 Global GLP-1 Analogues Market, by Geography (2019-2032)
- SECTION 12 - NORTH AMERICA GLP-1 ANALOGUES MARKET
- 12.1 North America Summary
- 12.2 Market Attractive Index
- 12.3 North America GLP-1 Analogues Market, by Product (2019-2032)
- 12.4 North America GLP-1 Analogues Market, by Format (2019-2032)
- 12.5 North America GLP-1 Analogues Market, by Route of Administration (2019-2032)
- 12.6 North America GLP-1 Analogues Market, by Indication (2019-2032)
- 12.7 North America GLP-1 Analogues Market, by End Use (2019-2032)
- 12.8 North America GLP-1 Analogues Market, by Country (2019-2032)
- 12.8.1 U.S.
- 12.8.2 Canada
- 12.8.3 Mexico
- 12.8.4 Rest of North America
- SECTION 13 - EUROPE GLP-1 ANALOGUES MARKET
- 13.1 Europe Summary
- 13.2 Market Attractive Index
- 13.3 Europe GLP-1 Analogues Market, by Product (2019-2032)
- 13.4 Europe GLP-1 Analogues Market, by Format (2019-2032)
- 13.5 Europe GLP-1 Analogues Market, by Route of Administration (2019-2032)
- 13.6 Europe GLP-1 Analogues Market, by Indication (2019-2032)
- 13.7 Europe GLP-1 Analogues Market, by End Use (2019-2032)
- 13.8 Europe GLP-1 Analogues Market, by Country (2019-2032)
- 13.8.1 Germany
- 13.8.2 U.K.
- 13.8.3 France
- 13.8.4 Italy
- 13.8.5 Spain
- 13.8.6 Russia
- 13.8.7 The Netherlands
- 13.8.8 Belgium
- 13.8.9 Turkey
- 13.8.10 Rest of Europe
- SECTION 14 - ASIA-PACIFIC GLP-1 ANALOGUES MARKET
- 14.1 Asia-Pacific Summary
- 14.2 Market Attractive Index
- 14.3 Asia-Pacific GLP-1 Analogues Market, by Product (2019-2032)
- 14.4 Asia-Pacific GLP-1 Analogues Market, by Format (2019-2032)
- 14.5 Asia-Pacific GLP-1 Analogues Market, by Route of Administration (2019-2032)
- 14.6 Asia-Pacific GLP-1 Analogues Market, by Indication (2019-2032)
- 14.7 Asia-Pacific GLP-1 Analogues Market, by End Use (2019-2032)
- 14.8 Asia-Pacific GLP-1 Analogues Market, by Country (2019-2032)
- 14.8.1 China
- 14.8.2 India
- 14.8.3 Japan
- 14.8.4 South Korea
- 14.8.5 Singapore
- 14.8.6 Malaysia
- 14.8.7 Australia
- 14.8.8 Thailand
- 14.8.9 Philippines
- 14.8.10 Rest of Asia-Pacific
- SECTION 15 - SOUTH AMERICA GLP-1 ANALOGUES MARKET
- 15.1 South America Summary
- 15.2 Market Attractive Index
- 15.3 South America GLP-1 Analogues Market, by Product (2019-2032)
- 15.4 South America GLP-1 Analogues Market, by Format (2019-2032)
- 15.5 South America GLP-1 Analogues Market, by Route of Administration (2019-2032)
- 15.6 South America GLP-1 Analogues Market, by Indication (2019-2032)
- 15.7 South America GLP-1 Analogues Market, by End Use (2019-2032)
- 15.8 South America GLP-1 Analogues Market, by Country (2019-2032)
- 15.8.1 Brazil
- 15.8.2 Argentina
- 15.8.3 Chile
- 15.8.4 Colombia
- 15.8.5 Rest of South America
- SECTION 16 - MIDDLE EAST AND AFRICA GLP-1 ANALOGUES MARKET
- 16.1 Middle East and Africa Summary
- 16.2 Market Attractive Index
- 16.3 Middle East and Africa GLP-1 Analogues Market, by Product (2019-2032)
- 16.4 Middle East and Africa GLP-1 Analogues Market, by Format (2019-2032)
- 16.5 Middle East and Africa GLP-1 Analogues Market, by Route of Administration (2019-2032)
- 16.6 Middle East and Africa GLP-1 Analogues Market, by Indication (2019-2032)
- 16.7 Middle East and Africa GLP-1 Analogues Market, by End Use (2019-2032)
- 16.8 Middle East and Africa GLP-1 Analogues Market, by Country (2019-2032)
- 16.8.1 Kingdom of Saudi Arabia
- 16.8.2 South Africa
- 16.8.3 U.A.E.
- 16.8.4 Egypt
- 16.8.5 Rest of Middle East and Africa
- SECTION 17 - COMPANY SHARE ANALYSIS
- 17.1 Global GLP-1 Analogues Market, Company Share Analysis
- 17.2 North America GLP-1 Analogues Market, Company Share Analysis
- 17.3 Europe GLP-1 Analogues Market, Company Share Analysis
- 17.4 Asia-Pacific GLP-1 Analogues Market, Company Share Analysis
- SECTION 18 - COMPANY PROFILES
- 18.1 Novo Nordisk A/S
- 18.1.1 Company Snapshot
- 18.1.2 Financial Overview
- 18.1.3 Product Portfolio
- 18.1.4 Recent Developments
- 18.2 Eli Lilly and Company
- 18.2.1 Company Snapshot
- 18.2.2 Financial Overview
- 18.2.3 Product Portfolio
- 18.2.4 Recent Developments
- 18.3 Sanofi
- 18.3.1 Company Snapshot
- 18.3.2 Financial Overview
- 18.3.3 Product Portfolio
- 18.3.4 Recent Developments
- 18.4 AstraZeneca
- 18.4.1 Company Snapshot
- 18.4.2 Financial Overview
- 18.4.3 Product Portfolio
- 18.4.4 Recent Developments
- 18.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd
- 18.5.1 Company Snapshot
- 18.5.2 Financial Overview
- 18.5.3 Product Portfolio
- 18.5.4 Recent Developments
- 18.6 GSK
- 18.6.1 Company Snapshot
- 18.6.2 Financial Overview
- 18.6.3 Product Portfolio
- 18.6.4 Recent Developments
- 18.7 Moderna
- 18.7.1 Company Snapshot
- 18.7.2 Financial Overview
- 18.7.3 Product Portfolio
- 18.7.4 Recent Developments
- 18.8 Merck & Co., Inc.
- 18.8.1 Company Snapshot
- 18.8.2 Financial Overview
- 18.8.3 Product Portfolio
- 18.8.4 Recent Developments
- 18.9 Hanmi Science
- 18.9.1 Company Snapshot
- 18.9.2 Financial Overview
- 18.9.3 Product Portfolio
- 18.9.4 Recent Developments
- 18.10 Zealand Pharma
- 18.10.1 Company Snapshot
- 18.10.2 Financial Overview
- 18.10.3 Product Portfolio
- 18.10.4 Recent Developments
- SECTION 19 - RELATED REPORTS
- SECTION 20 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.